Metformin as a lipid-lowering drug in non-diabetic patients

• Autor(a) principal: Dias, Patrícia
• Data de Publicação: 2004
• Outros Autores: Reis, Rita
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://revista.spmi.pt/index.php/rpmi/article/view/1763
• topic: metformina; dislipidémia; não diabetes; metformin; dyslipidemia; non-diabetic

OBJECTIVE: To evaluate the effect of therapy with metformin on the lipid profile of dyslipidemic, non-diabetic patients. METHODS: We studied the subgroup of non-diabetic patients from our Lipidology / Dyslipidemia outpatient clinic who were treated with metformin as first lipid lowering drug (n=17), and evaluated the lipid profile before and 3 months after introducing the drug. We compared the baseline characteristics of this group with those of a sample of non-diabetic dyslipidemic patients treated differently. RESULTS: Three months after introducing metformin, there was a 41,8% significant reduction of triglycerides (p=0.006), as well as a 10.4% reduction of total cholesterol and a 5.9% raise of HDL cholesterol, which did not reach statistical significance. LDL cholesterol did not vary significantely.The non-diabetic patients who were treated with metformin had lower mean HDL cholesterol and higher mean triglycerides than the other non-diabetics. CONCLUSION: Metformin emerges as a good lipid-lowering drug in non-diabetic patients, particularly for patients with hypertriglyceridemia and other features of the metabolic syndrome.